The Effect of Insulin Degludec Versus Insulin Glargine U100 on Glucose Metrics Recorded During Continuous Glucose Monitoring in People With Type 1 Diabetes and Recurrent Nocturnal Severe Hypoglycemia
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
The Effect of Insulin Degludec Versus Insulin Glargine U100 on Glucose Metrics Recorded During Continuous Glucose Monitoring in People With Type 1 Diabetes and Recurrent Nocturnal Severe Hypoglycemia. / Brøsen, Julie Maria Bøggild; Agesen, Rikke Mette; Alibegovic, Amra Ciric; Andersen, Henrik Ullits; Beck-Nielsen, Henning; Gustenhoff, Peter; Hansen, Troels Krarup; Hedetoft, Christoffer; Jensen, Tonny Joran; Juhl, Claus Bogh; Stolberg, Charlotte Røn; Lerche, Susanne Søgaard; Nørgaard, Kirsten; Parving, Hans Henrik; Tarnow, Lise; Thorsteinsson, Birger; Pedersen-Bjergaard, Ulrik.
In: Journal of Diabetes Science and Technology, 2024.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - The Effect of Insulin Degludec Versus Insulin Glargine U100 on Glucose Metrics Recorded During Continuous Glucose Monitoring in People With Type 1 Diabetes and Recurrent Nocturnal Severe Hypoglycemia
AU - Brøsen, Julie Maria Bøggild
AU - Agesen, Rikke Mette
AU - Alibegovic, Amra Ciric
AU - Andersen, Henrik Ullits
AU - Beck-Nielsen, Henning
AU - Gustenhoff, Peter
AU - Hansen, Troels Krarup
AU - Hedetoft, Christoffer
AU - Jensen, Tonny Joran
AU - Juhl, Claus Bogh
AU - Stolberg, Charlotte Røn
AU - Lerche, Susanne Søgaard
AU - Nørgaard, Kirsten
AU - Parving, Hans Henrik
AU - Tarnow, Lise
AU - Thorsteinsson, Birger
AU - Pedersen-Bjergaard, Ulrik
N1 - Publisher Copyright: © 2023 Diabetes Technology Society.
PY - 2024
Y1 - 2024
N2 - Aim: Comparing continuous glucose monitoring (CGM)-recorded metrics during treatment with insulin degludec (IDeg) versus insulin glargine U100 (IGlar-100) in people with type 1 diabetes (T1D) and recurrent nocturnal severe hypoglycemia. Materials and methods: This is a multicenter, two-year, randomized, crossover trial, including 149 adults with T1D and minimum one episode of nocturnal severe hypoglycemia within the last two years. Participants were randomized 1:1 to treatment with IDeg or IGlar-100 and given the option of six days of blinded CGM twice during each treatment. CGM traces were reviewed for the percentage of time-within-target glucose range (TIR), time-below-range (TBR), time-above-range (TAR), and coefficient of variation (CV). Results: Seventy-four participants were included in the analysis. Differences between treatments were greatest during the night (23:00-06:59). Treatment with IGlar-100 resulted in 54.0% vs 49.0% with IDeg TIR (70-180 mg/dL) (estimated treatment difference [ETD]: –4.6%, 95% confidence interval [CI]: –9.1, –0.0, P =.049). TBR was lower with IDeg at level 1 (54-69 mg/dL) (ETD: –1.7% [95% CI: –2.9, –0.5], P <.05) and level 2 (<54 mg/dL) (ETD: –1.3% [95% CI: –2.1, –0.5], P =.001). TAR was higher with IDeg compared with IGlar-100 at level 1 (181-250 mg/dL) (ETD: 4.0% [95% CI: 0.8, 7.3], P <.05) and level 2 (> 250 mg/dL) (ETD: 4.0% [95% CI: 0.8, 7.2], P <.05). The mean CV was lower with IDeg than that with IGlar-100 (ETD: –3.4% [95% CI: –5.6, –1.2], P <.05). Conclusion: For people with T1D suffering from recurrent nocturnal severe hypoglycemia, treatment with IDeg, compared with IGlar-100, results in a lower TBR and CV during the night at the expense of more TAR.
AB - Aim: Comparing continuous glucose monitoring (CGM)-recorded metrics during treatment with insulin degludec (IDeg) versus insulin glargine U100 (IGlar-100) in people with type 1 diabetes (T1D) and recurrent nocturnal severe hypoglycemia. Materials and methods: This is a multicenter, two-year, randomized, crossover trial, including 149 adults with T1D and minimum one episode of nocturnal severe hypoglycemia within the last two years. Participants were randomized 1:1 to treatment with IDeg or IGlar-100 and given the option of six days of blinded CGM twice during each treatment. CGM traces were reviewed for the percentage of time-within-target glucose range (TIR), time-below-range (TBR), time-above-range (TAR), and coefficient of variation (CV). Results: Seventy-four participants were included in the analysis. Differences between treatments were greatest during the night (23:00-06:59). Treatment with IGlar-100 resulted in 54.0% vs 49.0% with IDeg TIR (70-180 mg/dL) (estimated treatment difference [ETD]: –4.6%, 95% confidence interval [CI]: –9.1, –0.0, P =.049). TBR was lower with IDeg at level 1 (54-69 mg/dL) (ETD: –1.7% [95% CI: –2.9, –0.5], P <.05) and level 2 (<54 mg/dL) (ETD: –1.3% [95% CI: –2.1, –0.5], P =.001). TAR was higher with IDeg compared with IGlar-100 at level 1 (181-250 mg/dL) (ETD: 4.0% [95% CI: 0.8, 7.3], P <.05) and level 2 (> 250 mg/dL) (ETD: 4.0% [95% CI: 0.8, 7.2], P <.05). The mean CV was lower with IDeg than that with IGlar-100 (ETD: –3.4% [95% CI: –5.6, –1.2], P <.05). Conclusion: For people with T1D suffering from recurrent nocturnal severe hypoglycemia, treatment with IDeg, compared with IGlar-100, results in a lower TBR and CV during the night at the expense of more TAR.
KW - CGM
KW - insulin analogs
KW - time in range
KW - time-above-range
KW - time-below-range
KW - type 1 diabetes
U2 - 10.1177/19322968231197423
DO - 10.1177/19322968231197423
M3 - Journal article
C2 - 37671755
AN - SCOPUS:85170560705
JO - Journal of diabetes science and technology
JF - Journal of diabetes science and technology
SN - 1932-2968
ER -
ID: 387790608